Mecasermin (recombinant human insulin-like growth factor I)

Advances in Therapy

Volumn 26, Issue 1, 2009, Pages 40-54

  Rosenbloom, Arlan L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer risk; Cardiovascular risk; Diabetes mellitus; Growth; Growth hormone insensitivity; Insulin resistance; Neurodegenerative disease; Osteoporosis; Recombinant insulin like growth factor I; Retinopathy of prematurity

Indexed keywords

BRISBANE; HUMAN GROWTH HORMONE; MECASERMIN RINFABATE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FACIAL NERVE PARALYSIS; GENE MUTATION; GROWTH HORMONE DEFICIENCY; HIP FRACTURE; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTROPHY; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTRACRANIAL HYPERTENSION; LIPOHYPERTROPHY; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PAPILLEDEMA; PAROTID SWELLING; PREMATURITY; RETINOPATHY; REVIEW; SEIZURE; SHORT STATURE; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; TREATMENT DURATION; TREATMENT RESPONSE;

CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH DISORDERS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; JANUS KINASE 2; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 73449091835     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0136-5     Document Type: Review

References (81)

1. A.L. Rosenbloom 2007 The physiology of growth Ann Nestlé 65 97 108
2. A.M. de Vos M. Ultsch A.A. Kossiakoff 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex Science 255 306 312 1549776 10.1126/science.1549776
3. G.S. Campbell 1997 Growth-hormone signal transduction J Pediatr 131 S42 S44 9255227 10.1016/S0022-3476(97)70010-6 1:CAS:528:DyaK2sXls1Wjsb4%3D
4. E. Rinderknech R.E. Humbel 1978 The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin J Biol Chem 253 2769 2772
5. E. Rinderknech R.E. Humbel 1978 Primary structure of human insulin like growth factor II FEBS Lett 89 283 287 10.1016/0014-5793(78)80237-3 (Pubitemid 8340912)
6. R.G. Baxter M.A. Binoux D.R. Clemmons 1998 Recommendations for nomenclature of the insulin-like growth factor binding proteins superfamily J Clin Endocrinol Metab 83 3213 9745429 10.1210/jc.83.9.3213 1:CAS:528: DyaK1cXmt1ehu7c%3D (Pubitemid 28500960)
7. H.M. Domené S.V. Bengolea H.G. Jasper Y.R. Boisclair 2005 Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse J Endocrinol Invest 28 43 46 16114275
8. P.F. Collett-Solberg P. Cohen 2000 Genetics, chemistry, and function of the IGF/IGFBP system Endocrine 12 121 136 10905372 10.1385/ENDO:12:2:121 1:CAS:528:DC%2BD3cXjvFWht7g%3D
9. K.A. Woods C. Camacho-Hübner M.O. Savage A.J.L. Clark 1996 Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene N Engl J Med 335 1363 1367 8857020 10.1056/NEJM199610313351805 1:STN:280:DyaK2s%2FhtFSnsw%3D%3D (Pubitemid 26360455)
10. M.J. Walenkamp M. Karperien A.M. Pereira 2005 Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation J Clin Endocrinol Metab 90 2855 2284 15769976 10.1210/jc.2004-1254 1:CAS:528:DC%2BD2MXkt1Wgt7Y%3D (Pubitemid 40686336)
11. M.J. Abuzzahab A. Schneider A. Goddard 2003 IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation N Engl J Med 349 2211 2222 14657428 10.1056/NEJMoa010107 1:CAS:528:DC%2BD3sXps1Whs7w%3D (Pubitemid 37485137)
12. Y. Kawashima S. Kanzaki F. Yang 2005 Mutation at cleavage site of insulin like growth factor receptor in a short stature child born with intrauterine growth retardation J Clin Endocrinol Metab 90 4679 4687 15928254 10.1210/jc.2004-1947 1:CAS:528:DC%2BD2MXnvVWlu7o%3D (Pubitemid 41159358)
13. M.J.E. Walenkamp H.J. van der Kamp A.M. Pereira 2006 A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin like growth factor I receptor J Clin Endocrinol Metab 91 3062 3070 16757531 10.1210/jc.2005-1597 1:CAS:528:DC%2BD28XosFGhsbk%3D (Pubitemid 44271756)
14. K. Inagaki A. Tiulpakov P. Rubtsov 2007 A familial insulin like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization J Clin Endocrinol Metab 92 1542 1548 17264177 10.1210/jc.2006-2354 1:CAS:528:DC%2BD2sXksVSrtbg%3D (Pubitemid 46556437)
15. M.J.E. Walenkamp S.M.P.F. de Muinck Keizer-Schrama M. de Mos 2008 Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin like growth factor-I receptor due to a terminal 15q26.2->qter deletion detected by multiplex ligation probe amplification J Clin Endocrinol Metab 93 2421 2425 18349070 10.1210/jc.2007-1789 1:CAS:528:DC%2BD1cXntFamurg%3D (Pubitemid 351831568)
16. V. Hwa C. Camacho-Hübner B.M. Little 2007 Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene Horm Res 68 218 224 17389811 10.1159/000101334 1:CAS:528:DC%2BD2sXhtFWltr7O (Pubitemid 47525223)
17. L.C. Giudice F. de Zegher S.E. Gargosky 1995 Insulin like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth J Clin Endocrinol Metab 80 1548 1555 7538146 10.1210/jc.80.5.1548 1:CAS:528:DyaK2MXlsV2rsL0%3D
18. A.L. Rosenbloom J. Guevara-Aguirre R.G. Rosenfeld B.H. Pollock 1994 Growth in GH insensitivity Trends Endocrinol Metab 5 296 303 18407222 10.1016/1043-2760(94)P3205-L 1:CAS:528:DyaK2MXhvFWisbc%3D (Pubitemid 24329550)
19. O.G. Isaksson A. Lindahl A. Nilsson J. Isgaard 1987 Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth Endocr Rev 6 426 438
20. W.H. Daughaday P. Rotwein 1989 Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations Endocr Rev 10 68 91 2666112 1:CAS:528:DyaL1MXhs1Khsrc%3D 10.1210/edrv-10-1-68
21. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor (GHR): effects on growth, growth mediators and body composition. Presented at: Pediatric Academic Societies Meeting; May 3, 2008; Honolulu, Hawaii.
22. A. McDonald R.M. Williams F.M. Regan R.K. Semple D.B. Dunger 2007 IGF-I treatment of insulin resistance Eur J Endocrinol 157 S51 S56 17785698 10.1530/EJE-07-0271 1:CAS:528:DC%2BD2sXhtFKjtbzK (Pubitemid 47434131)
23. S.E. Kemp K.M. Thrailkill 2005 SomatoKine: is there a use in treating growth disorders? Curr Opin Investig Drugs 6 373 377 15898344 1:CAS:528:DC%2BD2MXktF2gsb4%3D
24. H.P. Guler J. Zapf E.R. Froesch 1987 Short-term metabolic effects and half-lives of intravenously administered insulin-like growth factor I in healthy adults N Engl J Med 317 137 140 3299085 1:CAS:528:DyaL2sXmtFantr4%3D
25. Rosenbloom AL, Ongley JP. Serum calcium phosphorus and magnesium decrement during oral glucose tolerance testing: alteration in pre-clinical and overt diabetes mellitus in childhood. In: Catin M, Selig M, eds. Magnesium in Health and Disease. Jamaica, NY: Spectrum Publishers Inc.; 1980: 297-304.
26. H.-P. Guler C. Schmid J. Zapp E.R. Froesch 1989 Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects Proc Natl Acad Sci U S A 86 2868 2872 2649897 10.1073/pnas.86.8.2868 1:CAS:528:DyaL1MXitVKmtLk%3D (Pubitemid 19112641)
27. M.A. Vaccarello F.B. Diamond Jr. J. Guevara-Aguirre 1993 Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome J Clin Endocrinol Metab 77 273 280 7686916 10.1210/jc.77.1.273 1:STN:280:DyaK3szhsFKjsQ%3D%3D (Pubitemid 23206815)
28. Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, eds. The IGF System: Molecular Biology, Physiology, and Clinical Applications. Totowa, NJ: Humana Press; 1999:739-769.
29. J. Guevara-Aguirre O. Vasconez V. Martinez 1995 A randomized double-blind, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in children with growth hormone 0 J Clin Endocrinol Metab 80 1393 1398 7536209 10.1210/jc.80.4.1393 1:CAS:528:DyaK2MXkvFejsbw%3D
30. H. Crosnier M. Gourmelen C. Prëvot R. Rappaport 1993 Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf J Clin Endocrinol 6 248 250 10.1210/jc.76.1.248 (Pubitemid 23027588)
31. K.F. Wilson P.J. Fielder J. Guevara-Aguirre 1995 Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency Clin Endocrinol 42 399 407 10.1111/j.1365-2265.1995.tb02649.x 1:STN:280: DyaK2M3mvFeltg%3D%3D
32. J. Guevara-Aguirre A.L. Rosenbloom O. Vasconez V. Martinez S.E. Gargosky R.G. Rosenfeld 1997 Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency J Clin Endocrinol Metab 82 629 633 9024266 10.1210/jc.82.2.629 1:CAS:528:DyaK2sXhtVWrsLo%3D (Pubitemid 27068641)
33. B. Klinger Z. Laron 1995 Three year IGF-I treatment of children with Laron syndrome J Ped Endocrinol Metab 8 149 158 1:STN:280:DyaK28%2FosVWhsA%3D%3D
34. M.B. Ranke M.O. Savage P.G. Chatelain M.A. Preece R.G. Rosenfeld P. Wilton 1999 Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes Horm Res 51 128 134 10461018 10.1159/000023345 1:CAS:528:DyaK1MXlt1ahtL8%3D (Pubitemid 29389370)
35. S.D. Chernausek P.F. Backeljauw J. Frane J. Kuntze L.E. Underwood 2007 GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity J Clin Endocrin Metab 92 902 910 10.1210/jc.2006-1610 1:CAS:528:DC%2BD2sXjtlGnu78%3D (Pubitemid 46465661)
36. Camacho-Hubner C, Underwood LE, Yordam N, et al. Once daily rhIGF-I/rhIGFBP3 treatment improves growth velocity in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. Presented at: 88th Annual Meeting of The Endocrine Society; June 24-27, 2006; Boston, MA, 2006. Abstract OR 40-1.
37. K. Sjögren J.L. Liu K. Blad 1999 Liver-derived insulin-like growth factor-I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice Proc Natl Acad Sci U S A 96 7088 7092 10359843 10.1073/pnas.96.12.7088 (Pubitemid 29275014)
38. S. Yakar J.L. Liu B. Stannard 1999 Normal growth and development in the absence of hepatic insulin-like growth factor-I Proc Natl Acad Sci U S A 96 7324 7329 10377413 10.1073/pnas.96.13.7324 1:CAS:528:DyaK1MXltVOru78%3D (Pubitemid 29299660)
39. V. Hwa G. Haeusler K.L. Pratt 2006 Total absence of functional acid labile subunit, resulting in severe insulin like growth factor deficiency and moderate growth failure J Clin Endocrinol Metab 91 1826 1831 16507628 10.1210/jc.2005-2842 1:CAS:528:DC%2BD28XkslCntbs%3D
40. H.M. Domené S.V. Bengolea A.S. Martínez 2004 Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene N Engl J Med 92 570 577 10.1056/NEJMoa013100 (Pubitemid 38160787)
41. H.M. Domené P. Scaglia A. Lteif 2007 Phenotypic effects of null and haploinsufficiency of acid labile subunit in a family with two novel IGFALS gene mutations J Endocrinol Metab 92 4444 4450 10.1210/jc.2007-1152 1:CAS:528:DC%2BD2sXhtlartbjO (Pubitemid 350074768)
42. C. Camacho-Hübner S. Rose M.A. Preece 2006 Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome J Clin Endocrinol Metab 91 1246 1253 16403822 10.1210/jc.2005-1017 1:CAS:528:DC%2BD28XjvFOks7s%3D
43. R.G. Clark 2005 Recombinant insulin like growth factor-I as a therapy for IGF-I deficiency in renal failure Pediatr Nephrol 20 290 294 15682316 10.1007/s00467-004-1714-7 (Pubitemid 40309931)
44. A.L. Rosenbloom 2006 Is there a role for recombinant insulin-like growth factor-I (rhIGF-I) in the treatment of idiopathic short stature? Lancet 368 612 616 16905026 10.1016/S0140-6736(06)69205-2 1:CAS:528:DC%2BD28XotVCksLw%3D (Pubitemid 44192550)
45. Long-term treatment with rhIGF-I in GHIS. Available at: www.clinicaltrials.gov/ct2/show/NCT00571727?term=tercica&rank=10. Accessed December 20, 2008.
46. Treatment of children and adolescents with growth failure associated with primary insulin like growth factor I (IGF-I) deficiency. Available at: www.clinicaltrials.gov/ct2/show/NCT00330668?term=tercica&rank=2. Accessed December 20, 2008.
47. Prepubertal children with growth failure associated with primary insulin like growth factor I (IGFI) deficiency. Available at: www.clinicaltrials.gov/ ct2/show/NCT00572156?term=tercica&rank=3. Accessed December 20, 2008.
48. Recombinant human insulin like growth factor (rhIGF-I) treatment of short stature associated with IGF-I deficiency. Available at: www.clinicaltrials.gov/ ct2/show/NCT00125190?term=tercica&rank=7. Accessed December 20, 2008.
49. rhGH and rhIGF-I combination therapy in children with short stature associated with IGF-I deficiency. Available at: www.clinicaltrials.gov/ct2/show/ NCT00572156?term=tercica&rank=4. Accessed December 20, 2008.
50. P.J. Fielder D.L. Mortensen P. Mallet B. Carlsson R.C. Baxter R.G. Clark 1996 Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats Endocrinology 137 1913 1920 8612531 10.1210/en.137.5.1913 1:CAS:528:DyaK28XisFCqs7k%3D (Pubitemid 26133968)
51. A.L. Rosenbloom 2001 Hot topic. IGF-I treatment of diabetes Pediatr Diabetes 2 123 130 15016195 10.1034/j.1399-5448.2001.002003123.x 1:STN:280:DC%2BD2c7isFyrtw%3D%3D (Pubitemid 32734369)
52. Genentech discontinues IGF-I drug development effort in diabetes [press release]. San Francisco, CA: Genentech, Inc.; September 5, 1997. Available at: www.gene.com/gene/news/press-releases/display.do?method=detail&id=4842. Accessed December 20, 2008.
53. K. Cusi R. DeFronzo 2000 Recombinant human insulin like growth factor I treatment for one week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance J Clin Endocrinol Metab 85 3077 3084 10999789 10.1210/jc.85.9.3077 1:CAS:528:DC%2BD3cXmsVKrurY%3D
54. Study of recombinant human insulin like growth factor I in patients with severe insulin resistance. Available at: www.clinicaltrials.gov/ct2/show/ NCT00004419?term=IGF-I&rank=44. Accessed December 20, 2008.
55. Insulin like growth factor I (IGF-I) and amyotrophic lateral sclerosis (ALS) trial. Available at: www.clinicaltrials.gov/ct2/show/NCT00035815?term= IGFI&rank=2. Accessed December 20, 2008.
56. A 48-week (24 week baseline followed by a 24 week treatment) phase II pilot study of the tolerability and effect/efficacy of subcutaneously administered insulin like growth factor -1 (rhIGF) (CEP-151) in multiple sclerosis (MS) Patients. Available at: www.clinicaltrials.gov/ct2/show/ NCT00001669?term=IGF-I&rank=66. Accessed December 20, 2008.
57. Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in myotonic dystrophy type 1 (iPLEX). Available at: www.clinicaltrials.gov/ct2/show/NCT00233519?term= insmed&rank=2. Accessed December 20, 2008.
58. E.J. Sorenson A.J. Windbank J.N. Mandrekar 2008 Subcutaneous IGF-1 is not beneficial in 2-year ALS trial Neurology 71 1770 1775 19029516 10.1212/01.wnl.0000335970.78664.36 1:CAS:528:DC%2BD1cXhtlylurjK
59. V.A. Ezzat E.R. Duncan S.B. Wheatcroft M.T. Kearney 2008 The role of IGF-I and its binding proteins in the development of type II diabetes and cardiovascular disease Diab Obes Metab 10 198 211 10.1111/j.1463-1326.2007. 00709.x 1:CAS:528:DC%2BD1cXkt1Wjurk%3D (Pubitemid 351247336)
60. S. Marleau M. Mulumba D. Lamontagne H. Ong 2006 Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies Cardiovasc Res 69 26 35 16219302 10.1016/j.cardiores.2005.08.022 1:CAS:528:DC%2BD2MXhtlGisbzK (Pubitemid 41818969)
61. Differential effects of rhGH versus rhIGF-I on cardiovascular risk factors. Available at: www.clinicaltrials.gov/ct2/show/NCT00684957?term= tercica&rank=9. Accessed December 20, 2008.
62. S. Boonen C. Rosen R. Bouillon 2002 Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study J Clin Endocrinol Metab 87 1593 1599 11932288 10.1210/jc.87.4.1593 1:CAS:528:DC%2BD38XivFKlt7Y%3D (Pubitemid 34615245)
63. Descriptive study of recombinant human insulin like growth factor for osteoporosis in Werner syndrome. Available at: www.clinicaltrials.gov/ct2/show/ NCT00004815?term=IGF-I&rank=189. Accessed December 20, 2008.
64. Effects of rhIGF-I on bone metabolism in adolescent girls with anorexia nervosa. Available at: www.clinicaltrials.gov/ct2/show/NCT00720122?term= IGFI&rank=87. Accessed December 20, 2008.
65. L.E.H. Smith 2004 Can we restore aspects of the in utero environment in premature infants to prevent disease? Pediatrics 114 491 15286236 10.1542/peds.114.2.491 (Pubitemid 39006681)
66. Hansen-Pupp I, Engström E, Niklasson A, et al. Fresh-frozen plasma as a source of exogenous insulin like growth factor i in the extremely preterm infant. J Clin Endocrinol Metab. 2008; Nov 11 [Epub ahead of print].
67. Effect of Increlex™ on children with Crohn disease. Available at: www.clinicaltrials.gov/ct2/show/NCT00764699?term=tercica&rank=12. Accessed December 20, 2008.
68. Treatment for growth failure in patients with X-linked severe combined immunodeficiency: phase 2 study of insulin-like growth factor-1. Available at: www.clinicaltrials.gov/ct2/show/NCT00490100?term=IGF-I&rank=4. Accessed December 20, 2008.
69. Evaluation the growth factors (IGF-1,IGFBP-3 and HGH) in patients with chronic liver disease. Available at: www.clinicaltrials.gov/ct2/show/ NCT00679692?term=IGF-I&rank=20. Accessed December 20, 2008.
70. IGF-I therapy in patients with cystic fibrosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00566241. Accessed January 25, 2009.
71. Assessment of mechanisms of improved wound healing. Available at: http://clinicaltrials.gov/ct2/show/NCT00673309?term= mechanisms+of+improved+wound+healing&rank=1. Accessed January 25, 2009.
72. W.D. Dudgeon K.D. Phillips J.A. Carson 2006 Counteracting muscle wasting in HIV-infected individuals HIV Med 7 299 310 16945075 10.1111/j.1468-1293.2006. 00380.x 1:STN:280:DC%2BD28rit1amug%3D%3D (Pubitemid 43805690)
73. E.R. Hollis II P. Lu A. Blesch M.H. Yuszynski 2009 IGF-I gene delivery promotes cortical spinal neuronal survival but not regeneration after adult CNS injury Exp Neurol 215 53 59 18938163 10.1016/j.expneurol.2008.09.014 1:CAS:528:DC%2BD1cXhsFagurfL
74. E. Carro J.L. Trejo A. Gerber 2005 Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis Neurobiol Aging 27 1250 1257 16183170 10.1016/j.neurobiolaging.2005.06.015 1:CAS:528: DC%2BD28XntlClsL8%3D
75. K. Iwai T. Nakagawa T. Endo 2006 Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel Laryngoscope 116 529 533 16585854 10.1097/01.mlg.0000200791.77819.eb 1:CAS:528:DC%2BD28XjtFOrt7w%3D (Pubitemid 44318060)
76. A.L. Rosenbloom U. Francke R.G. Rosenfeld J. Guevara-Aguirre 1999 Growth hormone receptor deficiency in Ecuador J Clin Endocrinol Metab 84 4436 4443 10599699 10.1210/jc.84.12.4436 1:CAS:528:DyaK1MXotVGru78%3D (Pubitemid 30677656)
77. O. Vasconez V. Martinez A.L. Martinez 1994 Heart rate increase in patients with growth hormone receptor deficiency treated with insulin-like growth factor I Acta Paediatr 399 137 139 10.1111/j.1651-2227.1994.tb13307.x 1:STN:280:DyaK2M%2Fjs12jtA%3D%3D
78. Z. Laron S. Ginsberg P. Lilos M. Arbiv N. Vaisman 2006 Long-term IGF-I treatment of children with Laron syndromic increases adiposity Growth Horm IGF Res 16 61 64 16442822 10.1016/j.ghir.2005.12.001 1:CAS:528:DC%2BD28XhtlGnsrs%3D (Pubitemid 43205316)
79. E. Torjusen J. Calderon S.A. Rivkees 2008 Anaphylactic reaction to recombinant insulin-like growth factor-I J Pediatr Endocrinol Metab 21 381 384 18556970 1:CAS:528:DC%2BD1cXnvVCqsbs%3D
80. A.A. Samani S. Yakar D. LeRoith P. Brodt 2007 The role of IGF system in cancer growth and metastasis: overview and recent insights Endocr Rev 28 20 47 16931767 10.1210/er.2006-0001 1:CAS:528:DC%2BD2sXjtFCgsrg%3D (Pubitemid 46220849)
81. J.K. Perry B.S. Emerald H.C. Mertani P.E. Lovie 2006 The oncogenic potential of growth hormone Growth Horm IGF Res 16 277 289 17101287 10.1016/j.ghir.2006.09.006 1:CAS:528:DC%2BD28Xht1eqtLbE (Pubitemid 44793716)